Gene expression in response to anti-tumour intervention by polysaccharide-K (PSK) in colorectal carcinoma cells

Oncology Reports

Volumn 12, Issue 6, 2004, Pages 1287-1293

  Yoshikawa, Reigetsu ^a   Yanagi, Hidenori ^a   Hashimoto Tamaoki, Tomoko ^a   Morinaga, Tomonori ^a   Nakano, Yoshiro ^a   Noda, Masafumi ^a   Fujiwara, Yoshinori ^a   Okamura, Haruki ^a   Yamamura, Takehira ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Complementary and alternative medicine (CAM); Lymphotactin; Multidrug resistance protein 3; Pharmacokinetic modulating chemotherapy (PMC); Pirin; Transgelin

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; KRESTIN; PROTEIN P53; PROTEOGLYCAN; PS-K;

ARTICLE; CELL STRAIN HCT116; COLORECTAL TUMOR; DNA MICROARRAY; DRUG EFFECT; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIBIOTICS, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEOGLYCANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 16644367585     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.12.6.1287     Document Type: Article

References (42)

1. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 10: 896-903, 1992.
2. Kohne CH, Schoffski P, Wilke H, Kaufer C, Andreesen R, Ohl U, Klaasen U, Westerhausen M, Hiddemann W, Schott G, Harstick A, Bade J, Horster A, Schubert U, Hecker H, Dorken B and Schmoll HJ: Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol 16: 418-426, 1998. (Pubitemid 28135582)
3. Glimelius B. Hoffman K, Graf W, Pahlman L and Sjoden PO: Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. Cancer 73: 556-562, 1994. (Pubitemid 24046593)
4. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR and Delbanco TL: Unconventional medicine in the United Slates. Prevalence, costs, and pattern of use. N Engl J Med 328: 246-252, 1993. (Pubitemid 23035311)
5. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Kessler RC and van Rompay M: Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 280: 1569-1575 1998. (Pubitemid 28520643)
6. Agha-Mohammadi S and Lotze MT: Immunomodulation of cancer: potential use of selectively replicating agents. J Clin Invest 105: 1173-1176, 2000. (Pubitemid 30266067)
7. Ng TB: A review of research on the protein-bound polysaccharide (polysaccharopeptide, PSP) from the mushroom Coriolus versicolor (Basidiomycetes: Polyporaceae). Gen Pharmacol 30: 1-4, 1998.
8. Nakazato H, Koike A, Saji S. Ogawa N and Sakamoto J: Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet 343: 1122-1126, 1994. (Pubitemid 24142032)
9. Mitomi T, Tsuchiya S, Iijima N, Aso K, Suzuki K, Nishiyama K, Amano T, Takahashi T, Murayama N, Oka H, Oya K and Noto T: Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. Dis Colon Rectum 35: 123-130, 1992.
10. Ogoshi K, Satou H, Isono K, Mitomi T, Endoh M and Sugita M: Immunotherapy for esophageal cancer. A randomized trial in combination with radiotherapy and radiochemotherapy. Cooperative Study Group for Esophageal Cancer in Japan. Am J Clin Oncol 18: 216-222, 1995.
11. Hayakawa K, Mitsuhashi N, Saito Y, Nakayama Y, Furuta M, Nakamoto S, Kawashima M and Niibe H: Effect of Krestin as adjuvant treatment following radical radiotherapy in non-small cell lung cancer patients. Cancer Detect Prev 21: 71-77, 1997. (Pubitemid 27307074)
12. Ehrke MJ, Reino JM, Eppolito C and Mihich E: The effect of PS-K, a protein bound polysaccharide, on immune responses against allogeneic antigens. Int J Immunopharmacol 5: 35-42, 1983. (Pubitemid 13144336)
13. Hosokawa M, Mizukoshi T, Morikawa K, Xu ZY and Kobayashi H: The therapeutic effects of an immunopotentiator, PS-K, on 3-melhylcholanthrcne- induced autochthonous tumors in C57BL/6 mice in combination with the surgical removal of primary sites. Cancer Immunol Immunother 22: 181-185, 1986. (Pubitemid 16089194)
14. Hirose K, Zachariae CO, Oppenheim JJ and Matsushima K: Induction of gene expression and production of immunomodulating cytokines by PSK in human peripheral blood mononuclear cells. Lymphokine Res 9: 475-483, 1990. (Pubitemid 20384838)
15. Nio Y, Shiraishi T, Tsubono M, Morimoto H, Tseng CC, Imai S and Tobe T: In vitro immunomodulating effect of protein-bound polysaccharide, PSK on peripheral blood, regional nodes, and spleen lymphocytes in patients with gastric cancer. Cancer Immunol Immunother 32: 335-341, 1991.
16. Noguchi K, Tanimura H, Yamaue H, Tsunoda T, Iwahashi M, Tani M, Mizobata S, Hotta T, Arii K, Tamai M, et al: Polysaccharide preparation PSK augments the proliferation and cytotoxicity of tumor-infiltrating lymphocytes in vitro. Anticancer Res 15: 255-258, 1995.
17. Mickey DD, Bencuya PS and Foulkes K: Effects of the immunomodulator PSK on growth of human prostate adenocarcinoma in immunodeficient mice. Int J Immunopharmacol 11:829-838, 1989. (Pubitemid 19252370)
18. Saji S, Umemoto T, Sugiyama Y, et al: Indication of immunochemotherapy using PSK for gastric cancer from the standpoint of host factors and studies of antitumor effect and PSK mechanism. Biotherapy (Tokyo) 5: 1996-2004, 1991.
19. Goh HS, Chan CS, Khine K and Smith DR: p53 and the behaviour of colorectal cancer. Lancet 344: 233-234, 1994.
20. Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y, Girodet J, Salmon RJ and Thomas G: Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 106:42-48, 1994. (Pubitemid 24011863)
21. Yanagi H, Noda M. Yoshikawa R, Ikeuchi H, Gega M, Yamamura T and Kusunoki M: Randomized clinical trial of pharmacokinetic modulating chemotherapy (PMC) in combination with continuous 5-FU infusion plus oral UFT for adjuvant chemotherapy after curative resection for Dukes' C colorectal cancer patients. Proc Am Soc Clin Oncol 22: 293, 2003.
22. Yoshikawa R, Kusunoki M, Yanagi H, Noda M, Furuyama JI, Yamamura T and Hashimoto-Tamaoki T: Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulatina chemotherapy. Cancer Res 61: 1029-1037, 2001. (Pubitemid 32174421)
23. Ohwada S, Kawate S, Ikeya T, Yokomori T, Kusaba T, Roppongi T, Takahashi T, Nakamura S, Kawashima Y, Nakajima T and Morishita Y: Adjuvant therapy with protein-bound polysaccharide K and Tegafur/Uracil in patients with stage II or III colorectal cancer: randomized, controlled trial. Dis Colon Rectum 46: 1060-1068, 2003. (Pubitemid 36992988)
24. Kusunoki M, Yanagi H, Noda M, Yoshikawa R and Yamamura T: Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-FU infusion alone and oral UFT after resection of hepatic colorectal metastases. Cancer 89: 1228-1235, 2000.
25. Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E and Zlotnik A: Involvement of chemokine receptors in breast cancer metastasis. Nature 410: 50-56, 2001. (Pubitemid 32225831)
26. Kool M, van der Linden M, de Haas M, Scheffer GL, de Vree JM, Smith AJ, Jansen G, Peters GJ, Ponne N, Scheper RJ, Elferink RP, Baas F and Borst P: MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA 96: 6914-6919, 1999. (Pubitemid 29274984)
27. Uchiumi T, Hinoshita E, Haga S, Nakamura T, Tanaka T, Toh S, Furukawa M, Kawabe T, Wada M, Kagotani K, Okumura K, Kohno K, Akiyama S and Kuwano M: Isolation of a novel human canalicular multispecific organic anion transporter, CMOAT2/MRP3, and its expression in cisplatin-resistant cancer cells with decreased ATP-dependent drug transport. Biochem Biophys Res Commun 252: 103-110, 1998. (Pubitemid 28534634)
28. Tatebe S, Sinicrope FA and Kuo MT: Induction of multidrug resistance proteins MRP1 and MRP3 and γ-glutamylcysteine synthetase gene expression by nonsteroidal anti-inflammatory drugs in human colon cancer cells. Biochem Biophys Res Commun 290: 1427-1433, 2002. (Pubitemid 34687417)
29. Kelner GS, Kennedy J, Bacon KB, Kleyensteuber S, Largaespada DA, Jenkins NA, Copeland NG, Bazan JF, Moore KW, Schall TJ and Zlotnik A: Lymphotactin: a cytokine that represents a new class of chemokine. Science 266: 1395-1399, 1994.
30. Hedrick JA, Saylor V, Figueroa D, Mizoue L, Xu Y, Menon S, Abrams J, Handel T and Zlotnik A: Lymphotactin is produced by NK cells and attracts both NK cells and T-cells in vivo. J Immunol 158: 1533-1540, 1997. (Pubitemid 127469505)
31. Dilloo D, Bacon K, Holden W, Zhong W, Burdach S, Zlotnik A and Brenner M: Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat Med 2: 1090-1095, 1996. (Pubitemid 26338627)
32. Emtage PC, Wan Y, Hitt M, Graham FL, Muller WJ, Zlotnik A and Gauldie J: Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. Hum GeneTher 10: 697-709, 1999. (Pubitemid 29168155)
33. Zhang W, He L, Yuan Z, Xie Z, Wang J, Hamada H and Cao X: Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lymphotactin. Hum Gene Ther 10: 1151-1161, 1999. (Pubitemid 29233384)
34. Ju DW, Tao Q, Cheng DS, Zhang W, Zhang M, Hamada H and Cao X: Adenovirus-mediated lymphotactin gene transfer improves therapeutic efficacy of cytosine deaminase suicide gene therapy in established murine colon carcinoma. Gene Ther 7: 329-338, 2000. (Pubitemid 30119737)
35. 8+T-cells and neutrophils expressing XCR1 receptor. J Immunol 167: 57-65, 2001.
36. 8+T-cells and intratumoral lymphotactin transgene expression. Cancer Res 62: 2043-2051, 2002.
37. Rousseau RF, Haight AE, Hirschmann-Jax C, Yvon ES, Rill DR, Mei Z, Smith SC Inman S, Cooper K, Alcoser P, Grilley B, Gee A, Popek E, Davidoff A, Bowman LC, Brenner MK and Strother D: Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood 101: 1718-1726, 2003. (Pubitemid 36237566)
38. Thweatt R, Lumpkin CK Jr and Goldstein S: A novel gene encoding a smooth muscle protein is overexpressed in senescent human fibroblasts. Biochem Biophys Res Commun 187: 1-7, 1992.
39. Shields JM, Rogers-Graham K and Der CJ: Loss of transgelin in breast and colon tumors and in RIE-1 cells by Ras deregulation of gene expression through Rat-independent pathways. J Biol Chem 277: 9790-9799, 2002. (Pubitemid 34968082)
40. Wcndler WM, Kremmer E, Forster R and Winnacker EL: Identification of pirin, a novel highly conserved nuclear protein. J Biol Chem 272: 8482-8489, 1997. (Pubitemid 27147811)
41. Dechend R, Hirano F. Lehmann K, Heissmeyer V, Ansieau S, Wulczyn FG, Scheidereit C and Leutz A: The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-regulators. Oncogene 18: 3316-3323, 1999. (Pubitemid 29286977)
42. Orzaez D, de Jong AJ and Woltering EJ: A tomato homologue of the human protein PIRIN is induced during programmed cell death. Plant Mol Biol 46: 459-468, 2001. (Pubitemid 32665070) Technology